IBB News and Press, iShares Biotechnology ETF From 12/07/22

Summary Expectations surrounding central bank policy, China’s gradual reopening and a lower US dollar are key to investor sentiment in the final stretch of 2022. Central banks have increased interest rates at the fastest rate on record, and there are signs that higher yields are ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Summary Surging stocks show markets believe hopes of a soft landing by the Fed to be true. We disagree and stay underweight developed market (DM) stocks. U.S. stocks jumped and bond yields plunged after October CPI rose less than the market expected. But sticky core inflation keep...

Summary U.S. midterm elections: Win, lose or draw for markets? What sectors may benefit from a divided government. Will equity markets get the post midterm election bump? For further details see: U.S. Midterm Elections: Win, Lose Or Draw For Markets? ...

Summary Why the declines in tech on the S&P 500 may be hiding strength in other sectors from investors. The energy sector may still provide opportunities for investors. Insurers are not suffering the same challenges as other financials in the current high-rate environment....

Summary In today's issue of the 1-Minute Market Report, I examine the market bounce since the October low, and highlight the areas of the market that are leading the way higher. On Thursday, for every stock that was down, there were 26 that were up. For the first time since August...

Summary While a divided US government may look appealing, there are long-term risks amid resulting gridlock. The longest night belonged to the pollsters and pundits, whose predictions for a “red wave” did not come to fruition. Looking at historical relationships ...

Summary The private sector balance increased by a modest $22+ billion in October 2022. The shock change is bank credit creation, which is only a tiny $23B this last month and was almost zero last month. Fed rate rises are having an impact. The seasonal pattern is trending back...

Summary The drug-price reform focus of Congress affects biopharma stock prices. The likelihood that Republicans will control at least the House, is good for biotech stocks. The future of biotech stocks into 2023 will now depend more on the other key factors that drive the sect...

Summary In the healthcare provider space, nursing expense is the largest component of salaries, wages, and benefits. Barring another disruptive COVID surge, however, we believe the market for nurses is now coming back into balance. If the reduction in contract labor expense co...